Olaparib use in a patient diagnosed with BRCA2 mutated adrenocortical carcinoma: A case report

#3953

Introduction: Adrenocortical carcinoma (ACC) is a highly lethal endocrine malignancy with an estimated annual incidence of 1.5–2 cases per million. Only a small percentage of ACC cases are associated with hereditary cancer syndromes while, equally only a few cases, have been reported with BRCA mutation. Targeted therapy of ACC with germline mutations is an area of research which renders the treatment approach challenging.

Aim(s): Here, we present a case of ACC with a BRCA2 germline mutation which was subject to targeted therapy with olaparib.

Materials and methods: A 75-year-old female with a medical history of diabetes melitus type II, in April 2020 due to fatigue was diagnosed with an ACC of the right adrenal gland 6 x 5.2. x 4.7 cm. The woman underwent surgery but infiltration of the vena cava and rupture of the capsule was reported, and, due to the risk of recurrence, mitotatone was prescribed aside from hydrocortisone as implementation treatment. In July 2022 she had a recurrence and another surgery was performed with the goal of removing multiple implantations (R1 surgery). The patient refused to receive chemotherapy and Next-Generation Sequencing (NGS) was conducted with a BRCA2 gene deletion of exons 8-27 being detected. Besides the limited data the woman received olaparib off label as 1st line treatment.

Conference:

Presenting Author:

Authors: Kontana E, Tikas I, Boudina M, Chrysoulidou A, Andreadou A,

Keywords: adrenocortical carcinoma, brca2 mutation, olaparib,